iBio, Inc. filed an amendment to correct the expiration date of its Series G warrants to May 20, 2026, triggered by a clinical trial approval announcement, and provided updated warrant and share counts.
Key takeaways
Series G warrants will expire on May 20, 2026, triggered by a clinical trial approval announcement on April 8, 2026.
As of April 17, 2026, there are outstanding Series G warrants to purchase up to 11,065,000 shares of common stock.
If all outstanding Series G warrants are exercised, the company will issue 11,065,000 additional shares and corresponding Series H warrants.
The company received approval to initiate a Phase 1 clinical trial of IBIO-600 in Australia, with first participants expected in Q2 2026.
As of April 17, 2026, there are 36,143,561 shares of common stock outstanding.